(Q44838384)

6 December 2017

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance (English)

1 reference

6 December 2017

1 reference

1 reference

Hyesil Seol

1

1 reference

6 December 2017

Hyun Ju Lee

2

1 reference

6 December 2017

Yoomi Choi

3

1 reference

6 December 2017

Hee Eun Lee

4

1 reference

6 December 2017

Yu Jung Kim

5

1 reference

6 December 2017

Jee Hyun Kim

6

1 reference

6 December 2017

Eunyoung Kang

7

1 reference

6 December 2017

Sung-Won Kim

8

1 reference

6 December 2017

So Yeon Park

9

1 reference

6 December 2017

2 March 2012

1 reference

6 December 2017

1 reference

6 December 2017

25

1 reference

6 December 2017

938-948

1 reference

6 December 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.36

6 December 2017

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

HER-2/neu oncogene protein and prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

HER-2 gene amplification can be acquired as breast cancer progresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

HER-2/neu expression in primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its impl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Tumor heterogeneity: biological implications and therapeutic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Cancer as an evolutionary and ecological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.36

7 January 2021

10.1038/MODPATHOL.2012.36

Identifiers

DOI

1 reference

Dimensions Publication ID

6 December 2017

0 references

1 reference